What is Normunity?
Normunity operates at the intersection of immunology and oncology, developing a robust pipeline of therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. The company's core mission is to address untapped biology within the tumor microenvironment, specifically focusing on pathways that prevent effective tumor clearance. Its lead candidate, NRM823, is a T cell engager designed for tumor-specific targeting across multiple solid tumor indications. By leveraging proprietary insights into immune evasion, Normunity aims to redefine the standard of care for patients with limited treatment options, establishing a competitive market position through scientific innovation and strategic pharmaceutical partnerships.
How much funding has Normunity raised?
Normunity has raised a total of $140M across 2 funding rounds:
Series A
$65M
Series B
$75M
Series A (2022): $65M with participation from Osage University Partners, investorCanaan Ventures, Taiho Ventures, and Sanofi Ventures
Series B (2025): $75M led by Osage Venture Partners, Connecticut Innovations, Samsara BioCapital, Canaan Partners, Taiho Ventures, Sanofi Ventures, Enavate Sciences, Regeneron Ventures, Pfizer, and YK
Key Investors in Normunity
Samsara BioCapital
Samsara BioCapital is a specialized investment firm that partners with scientists and drug developers to create transformative therapeutics, focusing on driving innovation within the biopharmaceutical sector.
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies that align with the strategic interests of the parent pharmaceutical organization.
Taiho Ventures
Taiho Ventures, LLC is a strategic investment firm focused on the global biotech venture community, aiming to foster scientific advancements that provide significant value to Taiho Pharmaceutical Co., Ltd.
What's next for Normunity?
With the successful closure of this major enterprise-level funding, Normunity is well-positioned to execute its 2025 clinical roadmap. The primary strategic focus will be the initiation of human trials for NRM823, a critical inflection point that will validate the company's platform in a clinical setting. Beyond the lead program, the company is expected to continue expanding its pipeline of biologics, utilizing the recent capital to bolster its research and development infrastructure. As the firm moves into this capital-intensive phase, the continued support from its diverse investor base—ranging from corporate venture arms to specialized biotech funds—will be instrumental in navigating the complexities of drug development and potential future commercialization pathways.
See full Normunity company page
